(Pro(3)) GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy

Medicine and Dentistry

• Diabetes 100%
• Gastric Inhibitory Polypeptide 100%
• Receptor 11%
• Glucose Tolerance 7%
• In Vitro 3%
• Diabetic Obesity 3%
• In Vitro Production 3%
• Hyperinsulinemia 3%
• Diet Induced Obesity 3%
• Body Weight 3%
• Receptor Antagonist 3%
• Body Weight Gain 3%
• Ob/Ob Mouse 3%
• Insulin Sensitivity 3%
• Triacylglycerol 3%
• Dipeptidyl Peptidase IV 3%
• Proline 3%
• Macrogol 3%
• Treatment Group 3%

Biochemistry, Genetics and Molecular Biology

• Gastric Inhibitory Polypeptide 100%
• Gastric Inhibitory Polypeptide Receptor 18%
• Receptor Antagonist 4%
• Body Weight 4%
• Genetics 4%
• Insulin Blood Level 4%
• Ob/Ob Mouse 4%
• Triacylglycerol Blood Level 4%
• Dipeptidyl Peptidase 4%
• Insulin Sensitivity 4%
• Body Weight Gain 4%
• Cyclic Adenosine Monophosphate 4%
• Proline 4%

Pharmacology, Toxicology and Pharmaceutical Science

• Gastric Inhibitory Polypeptide 100%
• Gastric Inhibitory Polypeptide Receptor 18%
• Macrogol 4%
• Dipeptidyl Peptidase IV 4%
• Receptor Antagonist 4%
• Diabetic Obesity 4%
• Triacylglycerol 4%
• Diet Induced Obesity 4%
• Ob/Ob Mouse 4%
• Hyperinsulinemia 4%
• Proline 4%
• Treatment Group 4%